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Summary 
 
 
 
 
4-Methylethcathinone (2-(ethylamino)-1-(4-methylphenyl)propan-1-one), also known as 4-MEC, 
has emerged in recent years as a recreational psychostimulant. Its homolog mephedrone (4-
methylmethcathinone) is listed as a Schedule II substance under the 1971 United Nations 
Convention on Psychotropic Substances. The first official notification submitted to the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) by a European member state was 
2010. Since then it has been detected across the globe and marketed as a “research chemical” 
although it has also been detected as a constituent in branded products available for purchase via 
the Internet or brick-and-mortar shops.  
 
At the 36
th
 meeting of the WHO Expert Committee on Drug Dependence in June 2014, the 
Committee discussed a critical review report on 4-MEC and recommended that 4-MEC not be 
placed under international control at that time due to insufficiency of data regarding dependence, 
abuse and risks to public health but be kept under surveillance.  
 
The majority of literature published since the 36
th
 ECCD meeting deals with methods of chemical 
analysis but additional data are available from in vitro and in vivo studies. 4-MEC is a 
psychostimulant with monoamine transporter activity with indications of abuse liability. Some 
data obtained from the analysis of user reports suggest that 4-MEC produces euphoria, a sense of 
well being, psychostimulant effects and lack of comedown symptomatology and that these appear 
to be less intense and short-lived compared to mephedrone. Conflicting information is available 
related to the urge of redosing, craving and bingeing. Negative effects associated with 4-MEC use 
include excessive sweating in the armpits, nausea, and vomiting but also jaw clenching, 
nystagmus, heart palpitations, loss of sight and migraine.  
 
The available data so far also suggest that it may also function as a serotonin releasing agent but 
not dopamine, which would differentiate it from its homolog mephedrone. Further studies are 
needed to assess the dependence potential. The number of case reports that demonstrate a causal 
relationship between 4-MEC consumption and fatal intoxication is relatively limited. There is no 
known therapeutic and medical use. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
38
th
 ECDD (2016) Agenda item 4.3  4-MEC 
 
 
 
Page 7 of 38 
1.   Substance identification  
A. International Nonproprietary Name (INN) 
Not applicable 
B. Chemical Abstract Service (CAS) Registry Number 
1225617-18-4 (free base) 
  1266688-86-1 (hydrochloride salt) 
  1359736-80-3 (hydrobromide salt) 
  1346747-06-5 (N-C2D5 free base) 
  1346602-57-0 (N-C2D5 hydrochloride salt) 
  1388142-29-7 (R-enantiomer free base) 
  1388142-30-0 (S-enantiomer free base) 
C. Other Chemical Names 
4-MEC, 4-methylethcathinone, (±)-4'-methyl-N-ethylcathinone, 4-methyl-N-
ethcathinone, p-methyl-N-ethcathinone, 2-(ethylamino)-1-(p-tolyl)propan-1-one, p-
methylethcathinone. 
D. Trade Names 
Not applicable 
E. Street Names 
4-MEC 
F. Physical Appearance 
4-MEC HCl is a white crystalline powder. 
G. WHO Review History 
A critical review report on 4-MEC was discussed in June 2014 at the 36
th
 meeting 
of the WHO Expert Committee on Drug Dependence.
1
 The Committee 
recommended that 4-MEC not be placed under international control at that time due 
to insufficiency of data regarding dependence, abuse and risks to public health but 
be kept under surveillance.
2
 The majority of literature published since the 36
th
 
ECCD meeting deals with methods of chemical analysis but additional data are 
available from in vitro and in vivo studies. 4-MEC is a psychostimulant with 
monoamine transporter activity with indications of abuse liability. The available 
data so far also suggest that it may also function as a serotonin releasing agent but 
not dopamine, which would differentiate it from its homolog mephedrone.  
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2. Chemistry 
A. Chemical Name 
IUPAC Name: 2-(Ethylamino)-1-(4-methylphenyl)propan-1-one 
CA Index Name: 2-(Ethylamino)-1-(4-methylphenyl)-1-propanone 
B. Chemical Structure 
Free base: 
 
 
Note: Asterisk (*) refers to a chiral center 
 
Molecular Formula: C12H17NO 
Molecular Weight: 191.27 g/mol    
C. Stereoisomers 
The presence of a chiral centre at the α-carbon of the side chain gives rise to the 
enantiomeric pair of (S)-4-MEC and (R)-4-MEC, respectively. Available 
information suggests that the racemic form of 4-MEC is available on the market. 
D. Methods and Ease of Illicit Manufacturing 
Information about illicit manufacturing is unavailable. One approach to 4-MEC 
synthesis
3
 is based on a well-established standard procedure that includes the α-
bromination (step i) of the propan-1-one precursor (a) and formation of the 2-
bromoppropan-1-one intermediate (b). Reaction with N-ethylamine (step ii) gives 4-
MEC (c), which may then be converted into a range of salts. Illicit manufacturing of 
this substance is expected to be simple and straightforward. 
 
 
 
E. Chemical Properties 
Melting point (hydrochloride salt): 191 °C (dec.),
4
 210.4 °C,
5
 205 ± 3 °C.
6
 
Hydrobromide salt: 206.08 °C (acetone).
7, 8
  
Boiling point: Not reported. 
Solubility (hydrochloride salt): ~10 mg/mL in phosphate-buffered saline (pH 7.2); 
~12.5 mg/mL in DMF; ~30 mg/mL EtOH and DMSO.
9
  
CH3
O
H3C
H
N CH3*
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F. Identification and Analysis  
A range of routine and standard methods can be applied for the chemical analysis of 
4-MEC in tablet, powder or liquid form. More sensitive analytical techniques may 
be needed (e.g. single or multistage mass spectrometry detection) for the detection 
of this substance in biological matrices with low concentration. Table 1 (Annex 2) 
provides a list of representative examples published in the scientific literature since 
the 36
th
 meeting of the WHO Expert Committee on Drug Dependence.
1
 
 
3. Ease of Convertibility Into Controlled Substances 
No information available. 
 
4. General Pharmacology 
Similar to other well-researched psychostimulants, a key principle involved in the 
molecular mechanisms of 4-MEC is the interaction with transport proteins that lead to the 
elevation of extracellular neurotransmitter levels, most notably, dopamine (DA), 
norepinephrine (noradrenaline, NE) and serotonin (5-HT), respectively. The key targets of 
interest normally include the evaluation of drug action at the dopamine (DAT), 
norepinephrine (NET) and serotonin (SERT) transporters. An important question relates to 
the ability of a psychostimulant to act as a monoamine re-uptake inhibitor (e.g. cocaine-
like) or as a substrate-type releaser (amphetamine-like). In the latter case, this may be 
achieved by transporter-mediated translocation of the drug into the cytoplasm in exchange 
of the monoamine and increase of cytoplasmic levels by affecting storage in vesicles, thus 
leading to increasing monoamine availability for further release.
10
  
A. Routes of administration and dosage 
4-MEC is frequently taken by insufflation and oral administration (dissolved in liquids, 
encapsulated in capsules, or wrapped in paper). Other, less-favored routes that have been 
described by recreational users included “eyeballing,” rectal, and intravenous 
administration.
11
 However, 4-MEC, similar to some other ring-substituted synthetic 
cathinones, has also been reported to be injected by users who frequently inject other drugs 
(Section 14). 
  
Oral dosage levels have been tentatively suggested to range between 15-50 mg (threshold) 
and 150-300+ mg (strong) whereas threshold levels obtained from nasal insufflation were 
suggested to range between 5-25 mg (strong: 100-200 mg). The total duration of 
intoxication may last between 2-5 hours (p.o.) or 2-3 hours via nasal insufflation.
12, 13
  
B.  Pharmacokinetics 
Data from forensic toxicology casework suggest that 4-MEC is still detectable as the parent 
drug in biological matrices (blood and urine) (Table 4, Section 5). Data on detection 
windows of 4-MEC are not available but information about the identity of metabolites has 
been obtained from in vitro studies with human liver microsomes,
14, 15
 and from analyses of 
biological specimen.
15-17
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Overall, the key steps involved include reduction of the keto group, N-deethylation, 
hydroxylation of the 4-methyl group followed by further oxidation to the corresponding 4-
carboxy metabolite, and combinations of these steps. In one study, glucuronidation could 
only be observed for the hydroxy-tolyl metabolite.
15
 4-MEC, dihydro-4-MEC, N-deethyl-4-
MEC and N-deethyl-dihydro-4-MEC were identified in human urine
17
 although dihydro-4-
MEC might also be formed during storage in blood and plasma.
16
 4-MEC, dihydro-4-MEC, 
N-deethyl-4-MEC, N-deethyl-dihydro-4-MEC and hydroxytolyl-4-MEC have also been 
identified in forensic casework samples.
16
 Development of an analytical LC-MS
n
 screening 
method and application to authentic urine samples revealed the detection of 4-MEC, N-
deethyl-4-MEC, two N-deethyl-dihydro-4-MEC isomers, dihydro-4-MEC, 4-carboxy-4-
MEC and 4-carboxy-dihydro-4-MEC, respectively.
15
  
C. Pharmacodynamics 
Information about the in vitro properties of 4-MEC is summarized in Table 2. Available 
data suggest that 4-MEC primarily functions via its interaction with monoamine 
transporters, which is consistent with the profiles shown by other psychostimulants. 
However, important differences in their mode of action have come to light which might be 
relevant for the fact that 4-MEC has so far shown to be less potent than, for example, 
mephedrone in a variety of in vitro and in vivo assays (Table 3).  
 
In vitro pharmacology 
Whereas mephedrone has been shown to act as a non-selective substrate for DAT, NET 
and SERT,
18-20
 4-MEC has been revealed to show a ‘hybrid’ character,21 i.e. acting as a 
SERT substrate but as a DAT blocker in rat brain synaptosomes.
22
 Uptake inhibition at 
hNET
23-25
 and substrate-type behavior at NET have also been mentioned.
25
. Evaluation of 
the existing pharmacodynamic data (Table 2) indicates that 4-MEC is less potent than 
mephedrone in a variety of assays, possibly reflecting the induction of serotonin release 
compared to catecholamine reuptake inhibition. Additional multi-target screens revealed 
some moderate to low affinity to a number of receptors with Ki values below 5.5 µM, such 
as 5-HT2A (3.8 µM), 5-HT2C (5.2 µM) 
24
 and Sigma2 (Ki = 1.718 µM).
23
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Table 2. 4-MEC in-vitro uptake and release data 
a 
Uptake inhibition
 
Release
 
Affinity
 
Ref 
DAT IC50/nM NET IC50/nM SERT IC50/nM DAT EC50/ 
nM 
(Emax %) 
NET EC50/nM 
(Emax %) 
SERT EC50/nM 
(Emax %) 
DAT Ki/nM NET Ki/nM SERT Ki/nM  
565 1,668 1,798 -- -- -- >10,000 >10,000 41 Iversen et 
al.
23
 
4,280 2,230 7,930 Inactive Inactive Yes 
b
 890 6,800 7,700 Simmler et 
al.
24
 
~800 nM 
c 
~3900 nM 
d 
 
-- 
-- 
~500 nM 
c 
~10,900 nM 
d 
 
Inactive Inactive ~100 nM
 c
 -- -- -- Saha et al.
22
 
960 930 218 >100,000 710 1,520 3,000
 
15,800 12,600 Boos
25
 
Additional 4-MEC in vitro data  
 
Binding affinity towards other receptors with Ki value below 10,000 nM: Sigma2 receptor (Ki = 1718 nM) following the NIMH-PDSP screening protocol.
26
 
Iversen et 
al.
23
 
 
Binding affinity towards other receptors with Ki value below 5,500 nM: 5-HT2A (Ki = 3800 nM) and 5-HT2C (Ki = 5200 nM).  
Simmler et 
al.
24
 
 
4-MEC evoked inward current in Xenopus oocytes expressing SERT. Greatest magnitude of current observed at 30 μM 4-MEC equivalent to 10 μM 5-HT.  
Saha et al.
22
 
 
Binding affinity towards rat and mouse trace amine-associated receptor 1 > 20 μM; also reported in ref24. 
Simmler et 
al.
27
 
 
Cell viability test using the MTT assay on isolated rat hepatocytes. EC50 for 4-MEC = 1.29 mM and other substances for comparison included 3,4-
methylenedioxymethamphetamine (MDMA) (EC50 = 0.754 mM), methylone (EC50 = 1.18 mM) and 3,4-methylenedioxypyrovalerone (MDPV) (EC50 = 0.742 mM), 
respectively. Drugs were exposed to cells for 48 h at 37 °C. 
Araújo et 
al.
28
 
 
Evaluation of potential cytotoxic effects using primary rat hepatocytes (PRH) and HepaRG cells. MTT assay: hepatocytes and HepaRG cells were exposed to test 
drugs for 24 h. 4-MEC: EC50 = 0.835 mM (PRH) and 3.905 mM (HepaRG) and comparison included MDMA: EC50 = 1.070 mM (PRH) and 3.854 mM (HepaRG), 
methylone: EC50 = 1.262 mM (PRH) and 5.623 mM (HepaRG), MDPV: EC50 = 1.070 mM (PRH) and 3.854 mM (HepaRG), respectively.  
 
All remaining tests performed in primary rat hepatocytes.  
 
Lactate dehydrogenase (LDH) assay: 4-MEC exposure (24 h) induced concentration-dependent LDH leakage (0.2-1.6 mM). At 1.6 mM 4-MEC was significantly less 
effective than MDMA (p<0.05).  
 
4-MEC displayed concentration-dependent reducing power (Fe
3+
 to Fe
2+
) but MDMA did not under the conditions used; MDPV induced a comparatively weak 
reducing potential.  
 
Valente et 
al.
29
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Formation of intracellular reactive oxygen (ROS) and nitrogen (RNS) species were observed following 4-MEC exposure (24 h) at 0.4-1.6 mM levels. The 0.4 mM 
and 1.6 mM levels induced higher ROS and RNS levels than MDMA (p<0.05).  
 
Intracellular levels of glutathione (GSH) and glutathione disulfide (GSSG, oxidized form) evaluated using the DTNB- GSSG reductase recycling assay. Reduction of 
GSH (1.6 mM 4-MEC, 24 h) and increase of GSSG 1.6 mM 4-MEC, 24 h) were observed.   
 
4-MEC did not induce a significant change in intracellular ATP levels (bioluminescence assay) compared to control.  
 
Compared to control, caspase 3, 8, and 9 activities were increased significantly following exposure of 4-MEC (1.6 mM, 24 h). No significant changes observed at 
0.2-0.8 mM levels.  
 
Hoechst 33342/propidium iodide fluorescent staining to assess morphological changes in hepatocytes undergoing apoptosis or necrosis. Fluorescence microscopy 
revealed that 4-MEC application (0.8 mM and 1.6 mM) resulted in formation of early and late apoptotic cells and necrotic cells (1.6 mM only). 
 
a
 Ref
23
: National Institute of Mental Health's Psychoactive Drug Screening Program (NIMH-PDSP).
26
 
 
b
 Ref 
24
: Qualitative assessment. 5-HT release, but not DA and NE, was considered statistically significant relative to pseudo efflux. Test drug was incubated at one concentration of 
100 μM test drug. Transporters were expressed in HEX 293 cells.   
 
c
 Ref
22
: Obtained from rat brain synaptosomes.  
 
d
 Ref
22
: Obtained from hDAT and hSERT expressed in HEK 293 cells. 
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In vivo pharmacology 
 
Information about the in vivo properties of 4-MEC is summarized in Table 3. The available data 
suggest that 4-MEC induced psychostimulant-type behavior somewhat comparable to 
methcathinone, amphetamine and cocaine. However, 4-MEC appeared to be much less potent, 
thus, requiring higher dosage levels.  
 
Table 3. In vivo assay data for 4-MEC
 
Behaviour Neurochemistry / physiological responses 
/ etc. 
Ref 
 
Locomotor activity: 
a 
 
4-MEC produced time- and dose-dependent 
stimulation of locomotor activity in doses from 30 
to 100 mg/kg (ED50 = 21.09 mg/kg). Comparison 
with methcathinone: ED50 = 1.39 mg/kg). 
 
4-MEC stimulant effects occurred within 30 min 
following injection and lasted 110 min. During the 
period of peak effect (30–60 min), locomotor 
activity increased to a peak of 190% of vehicle 
control following 10 mg/kg. In contrast to other 
test drugs,
 a
 4-MEC did not show an inverted U-
shape dose-response. Stimulant effects had a 
slower onset than for the other compounds (30-60 
min vs. 0-30 min). 
 
Drug discrimination:
 b
 
 
4-MEC fully substituted for the discriminative 
stimulus effects of methamphetamine and cocaine. 
ED50 = 8.69 mg/kg (methamphetamine trained 
rats), ED50 = 12.54 mg/kg (cocaine trained rats). 
Comparison with methcathinone: ED50 = 0.36 
mg/kg (methamphetamine trained rats), ED50 = 
0.52 mg/kg (cocaine trained rats). 
 
-- Gatch et al.
30
 
 
Drug discrimination:
 c 
 
4-MEC (1.0-8.0 mg/kg) did not substitute for 
methamphetamine at any dose tested.  
 
-- Naylor et al.
31
 
Locomotor activity: 
d
  
 
Small increases in forward locomotion and 
stereotypy at 3 mg/kg. Motor effects were short-
lived and quickly returned to baseline values by 60 
min after injection. 
 
Microdialysis (rat nucleus accumbens): 
d
 
Significant increase of extracellular 5-HT 
above baseline: 3.2-fold (1 mg/kg) and 6.9-
fold (3.0 mg/kg). No effect on DA at 1 
mg/kg but 1.9-fold increase of DA levels at 
3 mg/kg.  
  
Saha et al.
22
 
Intracranial self-stimulation (ICSS): 
e 
 
Maximal reductions in ICSS thresholds observed 
with 4-MEC at 30 mg/kg (~15%) and were 
comparable with those observed with 
methamphetamine and α‐ PVP tested at the 0.3-
-- Watterson et 
al.
32
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mg/kg dose (~14%). ED50 values: 4-MEC (6.41 
mg/kg), α‐ PVP (0.35 mg/kg), methamphetamine 
(0.20 mg/kg), MDPV (0.35 mg/kg), methylone 
(1.00 mg/kg).  
 
Locomotor activity and sensitization: 
f 
 
4-MEC (30 mg/kg) and methamphetamine (1 
mg/kg) significantly increased locomotor activity. 
4-MEC: 10 to 30 min, methamphetamine: 15 to 95 
min. A 3 or 10 mg/kg dose did not stimulate 
locomotor activity.  
 
Significant increase in total distance travelled 
following administration of methamphetamine (1 
mg/kg) over 7 consecutive days and at rechallenge 
on day 22 compared to day one. 4-MEC (3, 10, or 
30 mg/kg) did not induce increase activity of 
consecutive days with the exception of the 
rechallenge at day 22 (30 mg/kg). At rechallenge 
on day 22: 4-MEC (30 mg/kg) group exhibited 
enhanced locomotor activity from 5 to 35 min 
compared to methamphetamine (1 mg/kg), ranging 
from 5 to 100 min. Neither development nor 
expression of locomotor sensitization was 
observed with 4-MEC at 10 mg/kg.  
 
Elevated plus maze test: 
g  
 
Repeated injections of 4-MEC (30 mg/kg) 
decreased total travel distance with reduced 
percentages of travel distance and time spent in the 
open arm. Repeated methamphetamine 
administrations (3 mg/kg) significantly increased 
exploration. After a 2-week withdrawal period 
from chronic 4-MEC or methamphetamine 
injections, all rats exhibited abnormally reduced 
anxiety based on increased percentages of travel 
distance and time spent in the open arm.  
 
Conditioned place preference: (CPP):
 h 
 
Significant CPP at 10 mg/kg 4-MEC on day 9 and 
on day 24 (context-associated reinstatement test). 
No difference observed compared to 
methamphetamine that displayed CPP on both 
days at 1 mg/kg. 
-- Xu et al.
33
 
 
a
 Male Swiss-Webster mice (8 weeks old). Separate groups of 8 mice were injected with either 0.9% saline or a test 
drug (4-MEC at 3, 10, 30 or 100 mg/kg). Horizontal activity was measured for 8 h within 10-min periods. Behavioral 
observations were recorded on each mouse during the test sessions at 30, 120, and 480 min following 100 mg/kg 4-
MEC. Other drugs for comparison included methcathinone, pentedrone, pentylone, and 3-fluoromethcathinone (3-
FMC).  
 
b
 Male Sprague-Dawley rats (two-lever choice methodology) trained to discriminate methamphetamine (1 mg/kg) and 
cocaine (10 mg/kg) from saline. 4-MEC (i.p., 1-50 mg/kg) was administered 30 min prior to the start of the test 
session. 
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c
 Male Sprague-Dawley rats (70 days old) trained to discriminate methamphetamine (1 mg/kg) from saline. Three 
synthetic cathinones, (4-MEC; 1.0-8.0 mg/kg), 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP; 4.0-16.0 
mg/kg), and alpha-pyrrolidinopentiophenone (alpha-PVP; 0.25-2.0 mg/kg) were tested for their ability to substitute 
for methamphetamine. Cocaine (1.0-8.0 mg/kg) was used as positive and pentobarbital (1.0-8.0 mg/kg) as negative 
control. 4-MEC was administered 15 min prior to the start of the test session. 
 
d
 Male Sprague Dawley rats. Rats received two i.v. drug injections, 1 mg/kg at time 0 followed by 3 mg/kg at the 60 
min mark.
 
 
e
 Intracranial self-stimulation thresholds determined following acute 4-MEC administration (0.1, 0.5, 1 and 2 mg/kg, 
i.p.); bipolar electrode implanted into the medial forebrain bundLe. Drugs were administered 20 minutes prior to 
placement into ICSS procedures. Doses: 4-MEC (1-100 mg/kg) compared to alpha-pyrrolidinopentiophenone (α-
PVP) (0.1-5 mg/kg) and methamphetamine (0.1-3 mg/kg). A 100-mg/kg dose for 4-MEC and 5-mg/kg dose for α-
PVP were also administered for a subset of rats. However, ICSS thresholds increased instead of leading to a decrease.  
 
f
 Male Sprague Dawley rats were injected once daily either with saline, 4-MEC (3, 10, or 30 mg/kg), or 
methamphetamine (1 mg/kg) for 7 consecutive days. Two weeks after last injection, each rat received the same drug. 
Locomotor activity was assessed for 120 minutes. 
 
g
 Rats tested the day before the first drug injection, then 35 min following the first and last injections (3, 10, or 30 
mg/kg for 4-MEC; 3mg/kg for methamphetamine), followed by a test 2 weeks of withdrawal. 
 
h
 Rats received 4-MEC (1, 3, or 10 mg/kg, i.p.) or methamphetamine (1 mg/kg, i.p.) on days 1, 3, 5, and 7. Saline was 
administered on days 2, 4, 6, and 8. On days 9 and 24 (2 weeks after withdrawal), rats were allowed to explore the 
entire apparatus freely for 15 min. 
 
 
5. Toxicology 
Two in vitro studies have been published that report the evaluation of cytotoxicity using rat 
hepatocytes and HepaRG cells (Table 2). Under the conditions used (e.g. applied doses and 
incubation of test drugs for 48 h and 24 h at 37 °C), toxic effects were observed related to 
cell viability, oxidative stress and apoptosis.  
 
6. Adverse Reactions in Humans 
Since the previous critical review report on 4-MEC,
1
 a number of new cases associated with 
4-MEC intoxications and deaths have been reported in the scientific literature which are 
summarized in Table 4. In the majority of cases, the appearance of other substances and 
alternative causes of deaths (in case of fatal intoxications), however, placed a challenge on 
the ability to establish a direct link between 4-MEC intake and adverse drug reactions.  
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Table 4. Case reports associated with the involvement of 4-MEC reported in the scientific literature. 
Year Cases Patient, 
age 
Context/clinically related comments (examples) Ref 
2012 1 U a Fatal 4-MEC intoxication with blood levels of 1267 ng/mL; cited in ref 
34
. 
 
Rojek et al.
35
 
2013 3 30M, 
27M,  
UM 
a
 
Case 1 (fatal): Road traffic accident. Blood: 152 ng/mL 4-MEC and 0.12 
g/dL ethanol; urine: 122 ng/mL 4-MEC and 0.19 g/dL ethanol.  
 
Case 2 (fatal): Blood: 56 ng/mL 4-MEC, PMA (2347 ng/mL), PMMA 
(30 ng/mL), amphetamine (378 ng/mL), methamphetamine (48 ng/mL), 
tetrahydrocannabinol (THC, 1.3 ng/mL) and 11-nor-9-carboxy-THC 
metabolite (8.7 ng/mL); urine: PMA (50.1 μg/mL), PMMA (1.7 μg/mL), 
4-MEC (14.3 μg/mL), amphetamine and THCCOOH (54.7 ng/mL). 
Analysis of stomach contents: detection of PMA, PMMA and 4-MEC.  
 
Case 3 (NF,
 b
 clinical): White powder found in possession containing 4-
MEC (78% purity). Blood analysis: 46 ng/mL 4-MEC.  
 
2 Fatal, 1 NF:
 b 
Deaths not caused by 4-MEC intoxication. 
 
 Gil et al.
34
 
2013 1 30M Clinical case (NF
 b
): User reported consumption of 10 g 4-MEC and 5 g 
of a branded product (NRG3) over 3 days and developed sudden outburst 
of aggression and tachycardia. Urine: MDMA (20 ng/mL), MDPV (20 
ng/mL), 4-MEC (200 ng/mL). Hair: 4-MEC (30 ng/mg), MDPV (1 
ng/mg), MDMA + MDA (2 et 0,1 ng/mg), mephedrone (0,1 ng/mg), 
cocaine (1,7 ng/mg) and metabolites (BZE = 0,2 + EME = 0,02 ng/mg), 
tramadol (3,5 ng/mg), hydroxyzine (0.14 ng/mg), aripiprazole (11 
ng/mg) and haloperidol (0.01 ng/mg). Plasma: paracetamol (7 μg/mL), 
tramadol (465 ng/mL). 
Knapp et al.
36
 
2013 1 NR 
c
 One analytical confirmed case by retrospective analysis of information 
from poison information center (Jan 2007-Dec 2012). No details 
reported. 
Le Roux et al.
37
 
2014 1 36M Male (in psychotherapy for drug addiction and suicide attempts) found 
dead and suspected to be injecting drug user. Several marks from needle 
and a rectal foreign body were observed. Blood: hydroxyzine detected at 
therapeutic concentration (160 ng/mL); peripheral blood: 4-MEC at 
14,600 ng/mL. Case considered fatal 4-MEC intoxication.  
Bottinelli et al.
38
 
2014 28 NR 
c
 Review of casework carried out between Jan 2010 and Dec 2012. 28/203 
cases involved detection of 4-MEC. No clear link between blood 
concentration levels and outcome. Example for drug deaths (including 
polydrug use, median): 0.46, 2.50, 5.83, 17.3 ng/mL; examples for non-
fatal blood concentrations: 0.09, 0.20; examples for alternative causes of 
death: 0.28, 5.03 ng/mL.  
Elliott and 
Evans
39
 
2014 7 NR 
c
 Review of casework of samples submitted between January 2010 and 
August 2011. Seven out of 189 cases included the detection of 4-MEC. 
One case was reported to confirm 4-MEC as the only substance detected 
and the poison severity score (PSS) was classified as “minor” (PSS = 1) 
in this case.  
Helander et al.
40
 
2014 1 36M Fatal: Detected blood levels: 1200 ng/mL 4-MEC and 230 ng/mL 
amphetamine. 
Rojek et al.
41
 
2014 1 39M Clinical case (NF
 b
): injection of claimed 0.25-0.50 g of 4-MEC followed 
by -butyrolactone (GBL) consumption; patient found unconscious. Five 
hours following injection patient showed transient apnea requiring 
oxygen and stimulation. Patient woke up 30 min and remained confused 
for 4 h; discharged 13 h later. Blood and urine levels (8 h after injection): 
353 ng/mL and 100 mg/L for 4-MEC and 300 mg/L and 1000 mg/L for 
Turcant et al.
17
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-hydroxybutyric acid (GHB). 
2015 1 21M Clinical case (NF
 b
): Severe decrease platelet numbers 
(thrombocytopenia) reported and associated with smoking 4-MEC and 
JWH-018 for 6 months. Evidence and analytical confirmation related to 
the presence of these particular two substances were not available. 
Mocanu et al.
42
 
2015 1 NR 
c
 A death case was mentioned following consumption of a herbal mixture 
called “ACME” (containing JWH-210) and the ‘‘bath salt’’ product 
“9/11” (containing 4-methylethcathinone)”. No further details reported. 
Moosmann et al.
43
 
2016 2 22M, 
54M 
Case 1 (considered 4-MEC drug death): Believed to have insufflated an 
unknown quantity of an NPS along with consumption of alcohol and use 
of cannabis; collapsed, started to convulse, coughed up blood and died 
~4.5 h later in hospital. Femoral blood: ethanol (0.03 g/dL), 4-MEC (170 
ng/mL), paracetamol (5,000 ng/mL). Ethanol (0.027 g/dL), 4-MEC and 
paracetamol were detected in urine qualitatively. 
 
Case 2: Male found dead with plastic carrier bag taped over his head. 
Femoral blood: 4-MEC (1730 ng/mL), ethanol (0.229 g/dL), propranolol 
(36 ng/mL), venlafaxine (284 ng/mL) and its metabolite O-
desmethylvenlafaxine (205 ng/mL), diazepam (<5 ng/mL) and its 
metabolite nordiazepam (33 ng/mL). 4-MEC, ethanol, venlafaxine and 
O-desmethylvenlafaxine were detected qualitatively in urine. 
Propranolol and venlafaxine have been prescribed. Postmortem findings 
were consistent with asphyxia due to respiratory obstruction and 
significant left ventricular hypertrophy and coronary atheroma were 
reported.  
Smith et al.
44
 
a 
U: Unknown; UM: male with unknown age. 
b
 NF: Non-fatal. 
c
 NR: Not reported. 
 
7. Dependence Potential 
A. Animal Studies 
No information available.  
B. Human Studies 
An analysis of 23 individual user trip reports and 112 screenshots of general 4-MEC 
user discussion boards revealed that the urge to redose when using 4-MEC was 
considered weak and short-lived with low incidence of negative comedown 
symptomatology (compared to mephedrone) although users with a history of 
synthetic cathinone use and less potent experiences with 4-MEC reported higher 
and more frequent dosing.
11
  
 
8. Abuse Potential 
A. Animal Studies 
Data summarized in Table 3 suggest that 4-MEC shows potential for abuse. A 
comparison with psychostimulants such as mephedrone, cocaine and amphetamine 
suggest its potency may be lower as far as drug discrimination, locomotor activity 
and intracranial self-stimulation (ICSS) studies are concerned. A recent 
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microdialysis study carried out in conscious rats revealed a robust increase of 5-
HT levels in dialysate obtained from rat nucleus accumbens. At the doses tested, 
small increases in dopamine levels were detected,
22
 which might suggest a lower 
abuse potential compared to non-selective releasing agents such as mephedrone.
18, 
19
 This would be consistent with the data presented on reductions of ICSS 
thresholds at significantly higher dosage levels (Table 3). From this perspective, 4-
MEC might display a profile more comparable to MDMA and methylone rather 
than methamphetamine or α-PVP.32  
B. Human Studies 
Information from formal clinical studies is not available. 4-MEC shows a 
psychostimulant profile in self reported users.
11, 45
  
 
9. Therapeutic Applications and Extent of Therapeutic Use and 
Epidemiology of Medical Use 
Not applicable. 
 
10. Listing on the WHO Model List of Essential Medicines 
4-MEC is not listed on the WHO Model List of Essential Medicines. 
 
11. Marketing Authorizations (as a Medicinal Product) 
4-MEC is not marketed as a medicine. 
 
12. Industrial Use 
4-MEC has no reported industrial use. 
 
13. Non-Medical Use, Abuse and Dependence 
Household surveys that specifically probe for prevalence of 4-MEC do currently not appear 
to be available in the published literature. Synthetic cathinones analyzed in drug samples 
submitted to a Spanish low-threshold drug testing Service between 2010 and 2012 revealed 
that 237 were submitted or identified to contain synthetic cathinones. 4-MEC was detected 
in 9.28% of the cases (methylone: 24.9%, mephedrone: 24.5% and MDPV: 6.8%).
46
 
Misrepresentation and detection of 4-MEC was reported on two occasions where users 
believed to have acquired either MDMA or ketamine.
47
 The Trans European Drug 
Information (TEDI) project, where five low-threshold European drug-testing services 
collaborate (Spain, Switzerland, Belgium, Austria, Portugal, and the Netherlands) reported 
on the evaluation and analysis of samples derived from the cocaine, “ecstasy”, and 
amphetamine market. The study reported the results obtained from 45,859 drug samples 
collected between 2008 and 2013. 4-MEC was detected in samples derived from the 
“ecstasy” market (tablets and powders) in Austria (2011-2013), Spain (2013), Switzerland 
(2013) but not in the Netherlands.
48
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14. Nature and Magnitude of Public Health Problems Related to Misuse, 
Abuse and Dependence 
The Hungarian National Focal Point reported that 4-MEC and MDPV dominated 
cathinone-related seizures in 2011 and it was observed that reduced availability of heroin 
on the market coincided with increasing changes in patterns related to injecting drug use, 
which included the use of 4-MEC.
49
 A survey amongst a group of injecting users of new 
psychoactive substances, the highest mean number of times where 4-MEC was injected per 
day was 11.5,
50
 thus, higher than what might be expected from heroin use. The 
combination of changing patterns in injecting drug users to new psychoactive substances 
(especially psychostimulants), a propensity to increased frequency and needle sharing, and 
economic challenges on harm reduction services, indicates increased vigilance and 
monitoring of incidences related to viral and bacterial infection rates.
50-52
 Use of 4-MEC is 
also associated with the purchase of “research chemicals” or equivalent products via the 
Internet and possibly “smart” shops. Instances of misuse, abuse and dependence would be 
limited to individual users rather than the general population.  
 
15. Licit Production, Consumption and International Trade 
4-MEC is available as standard reference material and produced for scientific research by a 
number of commercial suppliers. Other uses are not known. 
 
16. Illicit Manufacture and Traffic and Related Information 
Reports have been received from the EMCDDA’s European Early-Warning System on new 
psychoactive substances that 4-MEC was encountered in seizures or as a used substance in 
Spain, Luxembourg, Greece, Turkey, Lithuania, Belgium, Norway, Italy, Austria, Slovakia, 
Malta, Slovenia, Croatia, Germany, Hungary, Bulgaria, France, Czech Republic, Finland, 
Denmark, and United Kingdom.
53
  
 
The Drug Enforcement Administration disclosed that 374 exhibits were reported for 4-MEC 
between January 2010 and November 2013 which was based on STRIDE (System to 
Retrieve Information from Drug Evidence) database queries.
54
 The National Forensic 
Laboratory Information System (NFLIS), which is dedicated to collect drug cases submitted 
to State and local laboratories in the United States registered 1952 reports containing 4-MEC 
between January 2010 and December 2013. In 2010, three out of 628 reports of synthetic 
cathinones from 27 States were reported to NFLIS.
55
 Between April 2010 and November 
2013, a total number of 78 encounters (shipments) with 4-MEC were identified by U.S. 
Customs and Border Protection.
56
 The NFLIS 2014 Midyear Report (revised 2016), 2014 
Annual Report and 2015 Midyear Report did not mention 4-MEC.
57-59
 
 
4-MEC was reported to be the most common substance found in pills sold as “ecstasy” in 
the region of Oceania (at least in the time frame up to 2013).
60
 Responses obtained to the 
UNODC questionnaire on NPS (up to 2012) revealed that 4-MEC was ranked fourth with 
regards to numbers of reports (38) received. This was only superseded by mephedrone (68 
reports), MDPV (61 reports), methylone (53 reports) whereas flephedrone was ranked fifth 
(35 reports).
61
 4-MEC was reported 150 times to the UNODC Early Warning Advisory on 
New Psychoactive Substances by 41 Countries since 2009 (data for 2015 not yet completed). 
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The highest number of reports was received in 2013 (Dr. Justice Tettey, UNODC, personal 
communication).
62
  
 
Also refer to Annex 1: Report on WHO questionnaire for review of psychoactive substances. 
 
17. Current International Controls and Their Impact 
4-Methylethcathinone (4-MEC) is not controlled under the 1961, 1971 or 1988 United 
Nation Conventions. 
 
18. Current and Past National Controls 
The EMCDDA received information from the National Focal Points that 4-MEC is 
controlled in Bulgaria, Czech Republic, Denmark, Estonia, Finland, France, Germany, 
Hungary, Ireland, Lithuania, Poland, Portugal, Romania, Slovakia, Slovenia, Sweden, 
United Kingdom and Turkey. The Russian Federation confirmed that 4-MEC is a 
controlled substance.
53
 4-MEC is controlled in the USA,
54
 Singapore and New Zealand. 
Also refer to Annex 1: Report on WHO questionnaire for review of psychoactive 
substances. 
 
19. Other Medical and Scientific Matters Relevant for a Recommendation on 
the Scheduling of the Substance 
          Not applicable. 
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metabolites of the novel psychoactive substance 4-methyl-N-ethyl-cathinone (4-MEC) in human 
urine and pooled liver microsomes by GC-MS and LC-HR-MS/MS techniques and of its 
detectability by GC-MS or LC-MSn standard screening approaches. Drug Test Anal 2015;7:368-
75. doi:10.1002/dta.1682  
 
16. Soh YNA, Elliott S. An investigation of the stability of emerging new psychoactive 
substances. Drug Test Anal 2014;6:696-704. doi:10.1002/dta.1576  
 
17. Turcant A, Boels D, Helfer AG, Ferec S, Bretaudeau-Deguigne M, Lelièvre B et al. Acute 
combined poisoning with the new designer drug 4-methyl-N-ethyl-cathinone (4-MEC) and 
gammabutyrolactone (GBL): A case report with different analytical approaches for identification 
of some metabolites. Toxicol Anal Clin 2014;26:119-27. doi:10.1016/j.toxac.2014.07.001  
 
18. Baumann MH, Ayestas Jr MA, Partilla JS, Sink JR, Shulgin AT, Daley PF et al. The 
designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine 
transporters in brain tissue. Neuropsychopharmacology 2012;37:1192-203.  
 
19. World Health Organization. Mephedrone. Critical review report. Agenda item 4.12. Expert 
Committee on Drug Dependence. Thirty-sixth Meeting. Geneva, Switzerland, 16-20 June 2014. 
Available at: http://www.who.int/medicines/areas/quality_safety/4_12_review.pdf [August 2016]. 
 
20. Baumann MH, Solis E, Jr., Watterson LR, Marusich JA, Fantegrossi WE, Wiley JL. Baths 
salts, spice, and related designer drugs: the science behind the headlines. J Neurosci 
2014;34:15150-8. doi:10.1523/JNEUROSCI.3223-14.2014  
 
21. Blough BE, Landavazo A, Partilla JS, Baumann MH, Decker AM, Page KM et al. Hybrid 
dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused 
therapeutics. ACS Med Chem Lett 2014;5:623-7. doi:10.1021/ml500113s  
 
22. Saha K, Partilla JS, Lehner KR, Seddik A, Stockner T, Holy M et al. 'Second-generation' 
mephedrone analogs, 4-MEC and 4-MePPP, differentially affect monoamine transporter function. 
Neuropsychopharmacology 2015;40:1321-31. doi:10.1038/npp.2014.325  
 
38
th
 ECDD (2016) Agenda item 4.3  4-MEC 
 
 
 
Page 23 of 38 
23. Iversen L, Gibbons S, Treble R, Setola V, Huang X-P, Roth BL. Neurochemical profiles of 
some novel psychoactive substances. Eur J Pharmacol 2013;700:147-51. 
doi:10.1016/j.ejphar.2012.12.006  
 
24. Simmler LD, Rickli A, Hoener MC, Liechti ME. Monoamine transporter and receptor 
interaction profiles of a new series of designer cathinones. Neuropharmacology 2014;79:152-60. 
doi:S0028-3908(13)00532-7 [pii] 
10.1016/j.neuropharm.2013.11.008 [doi]  
 
25. Data provision courtesy of Dr Terence L. Boos, Drug & Chemical Evaluation Section, 
Office of Diversion Control, Drug Enforcement Administration, August 2016. Data collection 
form part of a DEA-NIDA cooperation. 
 
26. National Institute of Mental Health's Psychoactive Drug Screening Program.University of 
North Carolina at Chapel Hill. Available at: https://pdspdb.unc.edu/pdspWeb/content/PDSP 
Protocols II 2013-03-28.pdf [August 2016]. 
 
27. Simmler LD, Buchy D, Chaboz S, Hoener MC, Liechti ME. In vitro characterization of 
psychoactive substances at rat, mouse, and human trace amine-associated receptor. J Pharmacol 
Exp Ther 2016;357:134-44. doi:10.1124/jpet.115.229765  
 
28. Araújo AM, Valente MJ, Carvalho M, Dias da Silva D, Gaspar H, Carvalho F et al. Raising 
awareness of new psychoactive substances: chemical analysis and in vitro toxicity screening of 
'legal high' packages containing synthetic cathinones. Arch Toxicol 2015;89:757-71. 
doi:10.1007/s00204-014-1278-7  
 
29. Valente MJ, Araujo AM, Bastos ML, Fernandes E, Carvalho F, Guedes de Pinho P et al. 
Characterization of hepatotoxicity mechanisms triggered by designer cathinone drugs (beta-keto 
amphetamines). Toxicological Sciences 2016. doi:10.1093/toxsci/kfw105  
 
30. Gatch MB, Rutledge MA, Forster MJ. Discriminative and locomotor effects of five 
synthetic cathinones in rats and mice. Psychopharmacology 2015;232:1197-205. 
doi:10.1007/s00213-014-3755-3  
 
31. Naylor JE, Freeman KB, Blough BE, Woolverton WL, Huskinson SL. Discriminative-
stimulus effects of second generation synthetic cathinones in methamphetamine-trained rats. Drug 
Alcohol Depend 2015;149:280-4. doi:10.1016/j.drugalcdep.2015.02.002  
 
32. Watterson LR, Burrows BT, Hernandez RD, Moore KN, Grabenauer M, Marusich JA et al. 
Effects of alpha-pyrrolidinopentiophenone and 4-methyl-N-ethylcathinone, two synthetic 
cathinones commonly found in second-generation "bath salts," on intracranial self-stimulation 
thresholds in rats. International Journal of Neuropsychopharmacology 2015;18. 
doi:10.1093/ijnp/pyu014  
 
33. Xu P, Qiu Y, Zhang Y, Betaai Y, Xu P, Liu Y et al. The effects of 4-methylethcathinone on 
conditioned place preference, locomotor sensitization, and anxiety-like behavior: a comparison 
with methamphetamine. International Journal of Neuropsychopharmacology 2016;19. 
doi:10.1093/ijnp/pyv120  
38
th
 ECDD (2016) Agenda item 4.3  4-MEC 
 
 
 
Page 24 of 38 
 
34. Gil D, Adamowicz P, Skulska A, Tokarczyk B, Stanaszek R. Analysis of 4-MEC in 
biological and non-biological material - three case reports. Forensic Sci Int 2013;228:E11-E5. 
doi:10.1016/j.forsciint.2013.03.011  
 
35. Rojek S, Kłys M, Maciów M, Kula K, Strona M. Two fatal cases of intoxication with 4-
MMC and 4-MEC - medicolegal expertise. Presented at the Annual Meeting of the International 
Association of Forensic Toxicologists, 4 June 2012, Hamamatsu, Japan, 2012 2012.  
 
36. Knapp A, Humbert L, Etting I, Abe E, Garnier R, Alvarez JC. Identification et dosage de la 
4-MEC (4-méthyléthylcathinone) et de la MDPV (3,4-méthylènedioxypyrovalérone) dans 
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par les phénéthylamines, étude rétrospective au Centre antipoison et de toxicovigilance d’Angers. 
Ann Toxicol Anal 2013;25:C37.  
 
38. Bottinelli C, Bevalot F, Boucher A, Le Meur C, Fanton L. P48: Death by 4-
methylethcathinone (4-MEC) overdose: a case report. Toxicol Anal Clin 2014;26:S50. 
doi:10.1016/S2352-0078(14)70109-X  
 
39. Elliott S, Evans J. A 3-year review of new psychoactive substances in casework. Forensic 
Sci Int 2014;243:55-60. doi:10.1016/j.forsciint.2014.04.017  
 
40. Helander A, Bäckberg M, Hultén P, Al-Saffar Y, Beck O. Detection of new psychoactive 
substance use among emergency room patients: results from the Swedish STRIDA project. 
Forensic Sci Int 2014;243:23-9. doi:10.1016/j.forsciint.2014.02.022  
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Annex 1: Report on WHO Questionnaire for Review of Psychoactive 
Substances for the 38th ECDD: Evaluation of 4-MEC 
 
Data was obtained from 47 Member States (6 AFR, 2 EMR, 26 EUR, 7 PAH, 1 SEAR and 5 
WPR).  
 
A total of 45 Member States (5 AFR, 2 EMR, 25 EUR, 6 PAH, 1 SEAR and 6 WPR) answered the 
questionnaire for 4-Methylethcathinone (4-MEC). Of these, 26 respondents (21 EUR, 2 PAH and 
3 WPR) had information on this substance.  
 
LEGITIMATE USE  
 
There were 25 countries that reported no approved medical products containing 4-MEC for human 
or veterinarian indications. There was also no reported industrial use in 22 countries.  
 
4-MEC is currently being used in medical or scientific research in one country for metabolism and 
abuse potential research. Importation is the origin/source of 4-MEC was reported when used for 
legitimate non-medical/non-scientific use.  
 
4-MEC was not reported to be used for any cultural, religious or ceremonial purposes in 22 
countries.  
 
EPIDEMIOLOGY OF NON-MEDICAL/NON-SCIENTIFIC USE – USE FOR 
PSYCHOACTIVE PURPOSES OR RECREATIONAL DRUG USE 
 
There were 18 countries that reported 4-MEC as being misused for its psychoactive properties (as 
a recreational drug). Common routes of administration for non-medical/non-scientific purposes are 
oral (13 countries), sniffing (10 countries), injection (4 countries), inhalation (2 countries) and 
smoking (1 country). The main route of administration for 4-MEC was specified as oral (7 
countries) followed by sniffing (2 countries), insufflation (1 country) and smoking (1 country). 
 
The most common formulation reported for non-medical/non-scientific purposes was powder (16 
countries), followed by tablets (5 countries), liquid or solution for oral administration/use (1 
country) and injectable formulations (1 country). One country also reported plant material 
impregnated with the 4-MEC being used as a formulation.  
 
There were 13 countries which reported that the source of 4-MEC for non-medical/non-scientific 
use was smuggling.  
 
Party settings, people attending parties or dance festivals, are specified as a subpopulation known 
to misuse 4-MEC by two countries. Another country specified that youths and young adults were a 
subpopulation known to misuse 4-MEC.  
 
The level of negative health-impact originating from this substance's non-medical consumption 
was reported as either negligible (2 countries), substantial (5 countries) or serious (5 countries). 
For the countries that indicated a substantial or serious level of negative health-impact, they 
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specified that it was due to the association of 4-MEC with adverse events (including intoxications, 
transmission of communicable diseases through injection drug use), and fatalities. It was also 
mentioned that the pharmacodynamics of 4-MEC relate to those of MDMA and amphetamine. It 
was also commented that 4-MEC is a potent cathinone.  
 
Five countries reported that there had been emergency room/department visits related to the non-
medical use of 4-MEC. A combined number of 1 case in 2010, 1 case in 2011 and 4 cases in 2014 
were reported. One country stated that it was implicated in one suicide and several hospitalisations 
in 2010/11. Two other countries specified that there had been a total of 2 emergency 
room/department visits but the details (including year) were not known.  
 
The adverse effects which presented for 4-MEC at the emergency room/department included 
tachycardia, motor disorder, high respiratory rate, sweating, vertigo, anxiety, visual hallucinations 
and delirium.  
 
In regards to the mortality rate, data was provided by 5 countries. The rate where only 4-MEC was 
involved included 1 case in 2011. The rate which included involvement of other substances was 
reported to be 2 cases in 2013 and 2 cases in 2016. Finally the rate, where it was unknown if other 
substances were involved was 1 case in 2011. Another country commented that there may be a 
higher number of cases because in their country there is no reporting obligation by hospitals, 
poison centers etc. 
 
STATUS OF NATIONAL CONTROL AND POTENTIAL IMPACT OF 
INTERNATIONAL CONTROL 
 
There were 24 countries reported that 4-MEC was under national control. The legislation the 
control is based upon included the Medicines Act (3 countries), Controlled Substances Act (18 
countries), Criminal Law Act (2 countries) and other specific legislation (3 countries stated it was 
specific legislation for new psychoactive substances). In two countries the control is a temporary 
provision. One country reported that the use of Analog Act was a challenge to implementing 
controls for 4-MEC, as analog status had to be determined for each case.  
 
The scope of the controls includes production (20 countries), manufacturing (22 countries), 
exporting (21 countries), importing (24 countries), distribution (23 countries), use (16 countries) 
and possession (22 countries).  
 
Reported illicit activities involving 4-MEC include manufacture of the substance by chemical 
synthesis (2 countries), production of consumer products (1 country), trafficking (16 countries), 
smuggling (1 country), diversion (2 countries), domestic internet sales (2 countries), internet sales 
from abroad (9 countries), internet sales from unknown locations (6 countries) and finally sales to 
people who use this substance (5 countries).  
 
There were 18 countries which completed the section on the number of seizures. The combined 
number of seizures was 362 (2014), 126 (2015) and 39 (2016 to date). One country commented 
that they had noticed a decline of cases as soon as the substance was placed under control by 
national legislation. 
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If 4-MEC was placed under international control, 24 countries responded that they would have the 
capacity to enforce the control at the national level. There were 24 countries which responded that 
they would have the forensic laboratory capacity to analyse the substance.  
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Annex 2: Representative examples of studies associated with the 
detection and chemical analysis of 4-MEC (amongst other 
substances) published in the scientific literature since the 36th 
meeting of the WHO Expert Committee on Drug Dependence in June 
2014. 
 
Table 1. 
a,1
 
Techniques 
b
 Comment Reference 
SRI-ToF-MS Compounds obtained from test purchases. Acton et al.
2
 
LC-ESI-MS/MS Development of screening method using dried blood 
spots (DBS). 
Ambach et al.
3
 
LC-ESI-Orbitrap-MS Analysis of anonymised pooled urine from portable 
street urinals (City of Westminster, London, UK). 
Detection of 4-MEC in three urinals in July 2012. 
Archer et al.
4
 
IMS Analysis of 4-MEC standard reference material. Armenta et al.
5
 
Immunoassays, LC-
MS/MS 
Evaluation of cross-reactivity in CEDIA, EMIT, and 
KIMS immunochemical screening assays for drugs of 
abuse; analysis of authentic urine samples. 
Beck et al.
6
 
GC-MS(/MS), LC-
DAD 
Quantification in blood obtained from a fatal 
intoxication case. 
Bottinelli 
7
 
Immunoassay, LC-Q-
Orbitrap-MS 
Evaluation of the Randox Drugs of Abuse V (DOA-V) 
Biochip Array Technology; screening of 20,017 
authentic military urine specimens.  
Ellefsen et al.
8
 
LC-DAD, LC-MS/MS, 
LC-QTOF-MS 
Detection of 4-MEC in 28 forensic toxicology cases out 
of 203 cases between 2010 and 2012. 
Elliott and Evans
9
 
LC-MS/MS 4-MEC identified in 7 out of 189 cases (January 2010 to 
August 2011) submitted for toxicological analysis from 
emergency departments or intensive care units in 
Sweden. 
Helander et al.
10
 
Color test Evaluation of reaction between 4-MEC and 2,4-
dinitrophenylhydrazine (Brady's reagent). 
Isaacs et al.
11
 
GC-MS, LC-DAD, 
GC-FID, Orbitrap 
MS/MS 
Analysis of branded products obtained from a local 
“head shop” in 2011. 
Leffler et al.
12
 
ME-FL, derivatization Analysis of seized tablets. Lloyd et al.
13
 
ATR-FTIR, GC-MS Analysis of street mephedrone (4-methylmethcathinone) 
samples. 4-MEC was detected in 10% of samples as an 
adulterant; 199 samples seized in South Wales (UK) 
between November 2011 and March 2013. 
Miserez et al.
14
 
LC-QTOF-MS Development of screening method in spiked urine 
samples. 
Paul et al.
15
 
LC-MS/MS Analysis of meconium and maternal hair. Pichini et al.
16
 
LC-MS/MS Analysis of biological samples obtained from two fatal 
intoxications. 
Rojek et al.
17
 
Electroanalytical 
sensing 
Voltammetric characterization of synthesized standards. Smith et al.
18
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Electroanalytical 
sensing, LC-UV, LC-
Orbitrap-MS 
Voltammetric characterization of synthesized standards 
and application to four branded products (January 
2013). 
Smith et al.
19
 
IMS-TOF-MS Characterization of collected standards. Sysoev et al.
20
 
LC-DAD, LC-MS/MS, 
LC-QTOF-MS 
Stability study in blood and plasma and detection in 
forensic casework samples. 
Elliott and Soh et 
al.
21
 
LC-MS/MS Detection in fatal intoxication. 
c
 Rojek et al.
17
 
GC-MS, LC-Orbitrap-
MS, NMR 
Analysis of seized samples. Strano Rossi et al.
22
 
LC-MS/MS Development of screening method in spiked human hair 
samples and application to authentic hair samples. 
Strano-Rossi et al.
23
 
CE and MEKC-DAD 
and MS/MS 
Analysis of standard reference material. Švidrnoch et al.24 
Immunoassay Sixteen immunoassay kits were obtained from four 
commercial manufacturers to evaluate cross-reactivities 
in human serum.  
Swortwood et al.
25
 
LC-DAD, GC-MS, LC-
MS/MS, LC-Q-
Orbitrap-MS 
Detection of 4-MEC and GHB (GBL consumption) in 
blood and urine in an intoxication case. 
Turcant et al.
26
 
Portable NIR, GC-MS Analysis of standard reference material and forensic 
samples. 
Tsujikawa et al.
27
 
GC-MS Screening of 34,561 authentic urine samples collected 
between February 2011-January 2013 (4-MEC positive: 
0.19%). 
Uralets et al.
28
 
GC-MS, FTIR, NMR, 
WD-XRF, UV-Vis 
Analysis of 13 branded products purchased in different 
‘‘smart shops’’ in the area of Lisbon, Portugal.  
Zancajo et al.
29
 
LC-MS/MS Development of screening method in spiked blood and 
human urine samples. 
Ambach et al.
30
 
GC-MS, NMR, 
elemental analysis 
Analysis of 27 branded products purchased in three 
different Portuguese “smartshops” during 2012 and 
2013 and evaluation of hepatotoxic effects in vitro.  
Araújo et al.
31
 
GC-MS, TOF-MS, LC-
DAD, ATR-FTIR, IMS 
Analysis of 38 purified new psychoactive substances 
(NPS).  
Armenta et al.
32
 
LC-TOF-MS Mixed-mode chromatography study using standard 
reference material. 
Clyde et al.
33
 
LC-Q-Orbitrap-MS Development of screening method in human urine and 
application to authentic urine specimen (4-MEC 
detected in 3/49 samples).  
Concheiro et al.
34
 
IMS, DART-QTOF-
MS 
Analysis of standard reference material. Gwak and Almirall 
et al.
35
 
GC-(EI/CI)-MS/MS Analysis of standard reference material. Gwak et al.
36
 
GC-MS, LC-Q-
Orbitrap-MS 
Phase I and phase II metabolism study in human urine 
and incubation in pooled human liver microsomes. 
Helfer et al.
37
 
CE-ESI-MS Analysis of standard reference material. Moini et al.
38
 
DLLME, LC-MS/MS Development of screening method in spiked blood and 
application to authentic forensic blood samples (4-MEC 
detected in 1/60). 
Odoardi et al.
39
 
38
th
 ECDD (2016) Agenda item 4.3  4-MEC 
 
 
 
Page 32 of 38 
SFC, LC-DAD, LC-
MS/MS 
Analysis of standard reference material. Pauk et al.
40
 
LC-MS/MS Development of screening method for analysis of 
wastewater and river water and application to authentic 
water samples in Croatia; 4-MEC not detected.  
Senta et al.
41
 
LC-AD Method development and application to five branded 
products (January 2013). 
Zuway et al.
42
 
ELISA, LC-DAD, LC-
MS/MS 
Detection of 4-MEC in 3/112 forensic blood samples 
(review).  
Adamowicz et al.
43
 
LC-MS/MS Method development and application to authentic 
samples. Detection of 4-MEC in 3/112 forensic blood 
samples. 
Adamowicz and 
Tokarczyk
44
 
CEC-DAD, SFC-DAD, 
LC-DAD 
Chiral analysis of purchased samples or police samples. Albals et al.
45
 
LC-QTOF-MS Development of screening method for analysis of 
sewage samples and pooled urinals from music festivals 
in Norway (4-MEC not detected). 
Baz-Lomba et al.
46
 
Color spot tests, LC-
DAD, GC-MS, TLC, 
UV-Vis 
Analysis and detection of NPS in samples from the 
ecstasy market (tablets and powders) in five European 
drug-testing services between 2008-2013.  
Brunt et al.
47
 
GC-MS, DART-Q-
Orbitrap-MS/MS 
Analysis of standard reference material and two tablets. Chen et al.
48
 
SFC-LC-DAD Chiral analysis of collected samples. Geryk et al.
49
  
LC-MS/MS Analysis of urban wastewater sampled in several cities 
in four European countries. 4-MEC was detected in 
samples obtained from two cities (Italy and UK). 
Gonzalez-Marino et 
al.
50
 
GC-MS Thermal degradation study using standard reference 
material. 
Kerrigan et al.
51
 
SERS, GC-MS, IR Analysis of seized tablets and standards. Lee et al.
52
 
VAMS, LC-MS/MS Development of screening method for analysis of urine, 
plasma and oral fluid and application to samples from 
self-reported users. 
Mercolini et al.
53
 
GC-MS, LC-Orbitrap-
MS 
4-MEC detected in 33/162 samples obtained from 
Internet purchases and seizures between 2013 and 2015. 
Odoardi et al.
54
 
LC-MS/MS Development of screening method in spiked human hair 
samples and application to authentic hair samples (4-
MEC detected in one sample). 
Salomone et al.
55
 
qNMR Evaluation of signal integration functionalities.  Schoenberger et 
al.
56
 
LC-UV Chiral separation of branded products obtained from 
“smart shops”31 
Silva et al.
57
 
LC-MS/MS Two fatal intoxications and detection in femoral blood 
and urine.  
Smith et al.
58
 
LC-TOF-MS Analysis of urine samples from volunteers at two 
healthcare centers (4-MEC detected in 1/101 samples). 
Sundström et al.
59
 
LC-MS/MS Development of screening method for analysis of blood 
samples and application to authentic forensic blood 
Vaiano et al 
60
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samples (4-MEC not involved). 
LC-DAD, NMR,  Chiral analysis of standards and donated samples. Wolrab et al.
61
 
a 
 As of August 2016. 
 
b
 SRI: selective reagent ionization; TOF: time-of-flight; MS: mass spectrometry; LC: liquid 
chromatography (various forms); ESI: electrospray ionization; MS/MS: tandem mass spectrometry; IMS: 
ion mobility spectrometry; Q: quadrupole; DAD: diode array detection; QTOF: quadrupole-time-of-
flight; GC: gas chromatography; FID: flame ionization detection; ME: microchip electrophoresis; FL: 
fluorescence detection; ATR-FTIR: attenuated total reflection Fourier transform infrared; NMR: nuclear 
magnetic resonance spectroscopy; CE: capillary electrophoresis; MEKC: micellar electrokinetic 
chromatography; GHB: γ-hydroxybutyric acid; GBL: γ-butyrolactone; NIR: near infrared spectroscopy; 
WD-XRF: wavelength dispersive X-ray fluorescence; UV-Vis: ultraviolet-visible light spectroscopy; 
DART: direct analysis in real time; EI: electron ionization; CI: chemical ionization; DLLME: dispersive 
liquid/liquid microextraction; SFC: supercritical fluid chromatography; AD: amperometric detection; 
ELISA: enzyme-linked immunosorbent assay; CEC: capillary electrochromatography; SERS: surface-
enhanced Raman spectroscopy; VAMS: volumetric absorptive microsampling; qNMR: quantitative 
NMR; 
 
 
c
 Article cited in previous Critical Review report
1
 as “in press”. 
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